2023 ESMO: B7-H3 Targeted ADCs Show Exceptional Efficacy in SCLC and sqNSCLC
Updates on the first human study data from Phase I/II show that B7-H3 targeted ADCs continue to demonstrate therapeutic potential. In recent years, antibody-drug conjugates (ADCs) have emerged as a new class of drugs that bring new “hope” to the treatment of advanced cancer patients due to their unique mechanisms of action. The B7 family … Read more